Effectiveness of Convalescent Plasma for Treatment of COVID-19 Patients
This article has been Reviewed by the following groups
Listed in
- Evaluated articles (ScreenIT)
Abstract
Background and objective
The outbreak of COVID-19 has become a global health concern. In this study, we evaluate the effectiveness and safety of convalescent plasma therapy in patients with severe and critically ill COVID-19.
Methods
Sixteen COVID-19 patients received transfusion of anti-COVID-19 antibody-positive convalescent plasma. The main outcome was time for viral nucleic acid amplification (NAA) test turning negative. Clinical laboratory parameters were measured at the baseline (d0) before plasma transfusion, and day 1 (d1), day 3 (d3) after transfusion as well.
Results
Among the 16 patients, 10 of them had a consistently positive result of viral NAA test before convalescent plasma transfusion. Eight patients (8/10) became negative from day 2 to day 8 after transfusion. Severe patients showed a shorter time for NAA test turning negative after transfusion (mean rank 2.17 vs 5·90, P = 0.036). Two critically ill patients transfused plasma with lower antibody level remained a positive result of NAA test. CRP level demonstrated a decline 1 day after convalescent plasma treatment, compared with the baseline ( P = 0.017). No adverse events were observed during convalescent plasma transfusion.
Conclusions
Viral NAA test of most patients with COVID-19 who received convalescent plasma transfusion turned negative on the 2nd to 8th days after transfusion, and the negative time of severe patients was shorter than that of critically ill patients.
Trial Registration
Chinese Clinical Trial Registry; No.: ChiCTR2000030627 URL: http://www.chictr.org
Article activity feed
-
SciScore for 10.1101/2020.08.02.20166710: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Institutional Review Board Statement IRB: This case series study was approved by the Ethics Committee of Scientific Research and Clinical Trials of the First Affiliated Hospital of Zhengzhou University and the Henan Provincial People’s Hospital, respectively.
Consent: Patients diagnosed as COVID-19 by the SARS-CoV-2 nucleic acid amplification (NAA) test were given the convalescent plasma treatment if they fulfilled the following criteria: Rapidly progressed, severe or critically ill patient10, with a written informed consent given by the patient or next-of-kin.Randomization not detected. Blinding not detected. Power Analysis not detected. Sex as a biological variable The donors should also meet the … SciScore for 10.1101/2020.08.02.20166710: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Institutional Review Board Statement IRB: This case series study was approved by the Ethics Committee of Scientific Research and Clinical Trials of the First Affiliated Hospital of Zhengzhou University and the Henan Provincial People’s Hospital, respectively.
Consent: Patients diagnosed as COVID-19 by the SARS-CoV-2 nucleic acid amplification (NAA) test were given the convalescent plasma treatment if they fulfilled the following criteria: Rapidly progressed, severe or critically ill patient10, with a written informed consent given by the patient or next-of-kin.Randomization not detected. Blinding not detected. Power Analysis not detected. Sex as a biological variable The donors should also meet the following criteria: recovered patients aged 18-55 years old, with the weight more than 50Kg for males and 45Kg for females, no blood-borne diseases, assessed by a clinician to be able to donate plasma, and gave a written informed consent by the donor. Table 2: Resources
Software and Algorithms Sentences Resources SPSS (version 21.0; SPSS) was used for statistical computation. SPSSsuggested: (SPSS, RRID:SCR_002865)Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).
Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.Results from TrialIdentifier: No clinical trial numbers were referenced.
Results from Barzooka: We did not find any issues relating to the usage of bar graphs.
Results from JetFighter: We did not find any issues relating to colormaps.
Results from rtransparent:- Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
- Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
- No protocol registration statement was detected.
-
